Helicobacter pylori is a spiral-shaped bacterium that colonizes the stomach lining of roughly half the world’s population, making it one of the most common chronic infections on Earth. Most carriers never develop symptoms, but in a significant minority the infection triggers persistent stomach inflammation that can lead to ulcers, chronic digestive complaints, and an elevated risk of gastric cancer. What makes H. pylori unusual among pathogens is its ability to thrive in the intensely acidic environment of the stomach, a place where almost no other bacteria can survive for long.
How H. Pylori Survives Stomach Acid
Your stomach maintains a pH hovering around 1.5 to 3.5, acidic enough to break down food and kill most microorganisms on contact. H. pylori gets around this by producing large amounts of an enzyme called urease, which breaks down urea (naturally present in gastric fluid) into ammonia and carbon dioxide. The ammonia neutralizes the acid in the bacterium’s immediate surroundings, creating a small pocket of near-neutral pH that keeps it alive long enough to burrow into the thick mucus layer lining the stomach wall.1PubMed. Mechanisms of acid resistance due to the urease system of Helicobacter pylori Once nestled in the mucus, the bacterium is largely shielded from the acid bath above it.
The chemistry is a bit more involved than simple acid neutralization. Inside the bacterial cell, ammonia generated by urease mops up hydrogen ions that leak in from the acidic environment, converting them to ammonium, which is then pumped out.2PubMed. Acid survival of Helicobacter pylori: how does urease activity trigger cytoplasmic pH homeostasis? Surface-associated urease is particularly important for surviving the initial acid exposure before the bacterium reaches the protective mucus.3PubMed Central. Structure, function and localization of Helicobacter pylori urease This urease system is so central to the organism’s biology that strains engineered without it cannot colonize the stomach at all.
How the Infection Spreads
Despite decades of research, the exact transmission route of H. pylori remains surprisingly uncertain. Person-to-person spread is the most widely accepted explanation, likely through oral-oral contact (saliva, vomit) or the fecal-oral route.4PubMed. Helicobacter pylori: epidemiology and routes of transmission The bacterium’s DNA has been found in saliva, dental plaque, vomit, gastric juice, and feces, so there is no shortage of potential exit points. Spread within families is particularly common, and if one household member is infected, reinfection rates after treatment go up for everyone else.5PubMed Central. Helicobacter pylori, transmission routes and recurrence of infection: state of the art
Environmental transmission also plays a role. H. pylori has been detected in food samples, including milk, vegetables, and meat, suggesting contaminated food can be a vehicle.6PubMed Central. Role of food in environmental transmission of Helicobacter pylori Contaminated well water has been linked to clinical infections in the United States, and in parts of the world where untreated water is common, waterborne transmission is likely a major source.4PubMed. Helicobacter pylori: epidemiology and routes of transmission Across the board, crowded living conditions, lower socioeconomic status, and poor sanitation are consistently associated with higher infection rates. Most people pick up the bacterium during childhood, and in high-prevalence countries infection rates in adults can exceed 80 percent.
Symptoms and the Silent Majority
The most frustrating thing about H. pylori from a clinical standpoint is that most infected people feel perfectly fine. Estimates vary, but roughly 80 to 85 percent of carriers remain asymptomatic for life. The bacterium causes chronic inflammation of the stomach lining in virtually every person it colonizes, but that inflammation does not always translate into noticeable symptoms.
When symptoms do appear, they tend to fall under the umbrella of dyspepsia: a gnawing or burning pain in the upper abdomen, bloating, nausea, and early fullness after eating. A population study found that people with H. pylori antibodies were more likely to report heartburn, nighttime abdominal pain, and nausea, and that asymptomatic infected people had a higher chance of developing dyspepsia during follow-up compared to uninfected people.7Gut. Relation between Helicobacter pylori infection and gastrointestinal symptoms and syndromes People with markers of acute (recent) infection were especially likely to experience nighttime pain, heartburn, nausea, and vomiting. These symptoms overlap heavily with other digestive conditions, which is one reason H. pylori often goes undiagnosed unless a doctor specifically tests for it.
The Link to Peptic Ulcers
Before H. pylori was identified in the early 1980s, peptic ulcers were blamed on stress, spicy food, and excess acid production. The discovery that a bacterium was involved overturned decades of medical thinking. H. pylori is now recognized as a major driver of peptic ulcer disease. The organism disrupts the protective mucus layer of the stomach, allowing gastric acid to damage the underlying tissue.8PubMed. The role of Helicobacter pylori in peptic ulcer disease Eradicating the bacterium dramatically reduces ulcer recurrence, which was the finding that cemented its causal role.
Where the inflammation settles in the stomach matters a great deal for what happens next. Inflammation concentrated in the antrum (the lower portion of the stomach) can drive the acid-producing cells in the upper stomach to overproduce acid, raising the risk of duodenal ulcers. Inflammation concentrated in the corpus (the main body of the stomach), on the other hand, tends to reduce acid production and increases the risk of gastric ulcers and, over time, gastric cancer.9PubMed. The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases The pattern of inflammation is influenced by the specific bacterial strain, the host’s genetics, and environmental factors.
Gastric Cancer and Other Malignancies
The World Health Organization classified H. pylori as a Class I carcinogen back in 1994, putting it in the same category as tobacco smoke and asbestos in terms of established cancer-causing agents. This does not mean it is equally dangerous in terms of individual risk; the vast majority of infected people will not develop cancer. But at a population level, H. pylori is the single most important risk factor for gastric adenocarcinoma, the most common type of stomach cancer worldwide.
The cancer pathway involves two reinforcing mechanisms. First, chronic inflammation of the stomach lining over years and decades damages cells and promotes genomic instability. Second, certain bacterial proteins directly interfere with host cell signaling, disrupting DNA repair and normal cell turnover.10PubMed Central. Helicobacter pylori and Gastric Cancer: Pathogenetic Mechanisms The process involves dysregulation of several cellular pathways that control growth, inflammation, and programmed cell death.11PubMed Central. Helicobacter pylori and gastric cancer: mechanisms and new perspectives Not all strains carry the same risk. Strains carrying the CagA virulence factor are particularly associated with more aggressive inflammation and tissue damage.12Dig Dis Sci. The Gastric Mucosa from Patients Infected with CagA+ or VacA+ Helicobacter pylori Has a Lower Level of Dual Oxidase-2 Expression than Uninfected or Infected with CagA−/VacA− H. pylori
Beyond adenocarcinoma, H. pylori is the primary cause of gastric MALT lymphoma, a low-grade cancer of immune tissue in the stomach lining. MALT lymphoma accounts for roughly 7 to 9 percent of all B-cell lymphomas, and it stands out in oncology because in its early stages it can often be cured simply by eliminating the infection. Across studies, about 60 to 90 percent of patients with early-stage gastric MALT lymphoma achieve complete remission after H. pylori eradication therapy, with no chemotherapy or radiation required.13PubMed Central. Regression of Advanced Gastric MALT Lymphoma after the Eradication of Helicobacter pylori Even in some advanced cases, eradication alone has led to complete regression of disease, including metastases. In a study of 105 patients with localized gastric MALT lymphoma, roughly three-quarters achieved histological regression after eradication treatment alone.14PubMed. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type
How H. Pylori Is Diagnosed
Diagnosis can be either non-invasive or invasive, and the choice depends on the clinical situation. For most people, a non-invasive test is sufficient. The two workhorses are the urea breath test (UBT) and the stool antigen test. In the UBT, you swallow a capsule or drink a solution containing labeled urea. If H. pylori is present in your stomach, its urease enzyme breaks down the urea, and the labeled carbon dioxide shows up in your breath. Both the UBT and stool antigen test work well for initial diagnosis and for confirming that treatment has worked.15PubMed Central. Non-invasive tests for the diagnosis of helicobacter pylori: state of the art The stool test tends to be cheaper with comparable accuracy. Blood antibody tests (serology) are also available, but they cannot distinguish between a current and a past infection, which limits their usefulness for guiding treatment.
A meta-analysis comparing these methods in elderly patients found that the UBT had the highest diagnostic accuracy, followed by the stool antigen test, with serology trailing behind.16PubMed Central. A comparative systematic review and meta-analysis on the diagnostic accuracy of non-invasive tests for Helicobacter pylori detection in elderly patients When an endoscopy is performed for other reasons (to investigate an ulcer or rule out cancer), the rapid urease test (RUT) can be done on a small tissue sample taken during the procedure. The RUT is quick and cheap, with generally high sensitivity and specificity, but it can give false negatives if you have recently taken antibiotics or proton pump inhibitors.17PubMed Central. Diagnosis of Helicobacter pylori using the rapid urease test
Treatment and the Resistance Problem
Standard treatment involves a combination of a proton pump inhibitor (the kind of drug that reduces stomach acid) and two or more antibiotics, taken for 10 to 14 days. The classic regimen is called triple therapy: a proton pump inhibitor plus two antibiotics, traditionally clarithromycin and amoxicillin. Quadruple therapy adds a bismuth compound and substitutes or adds different antibiotics. In a recent comparison, triple therapy achieved eradication in about 68 percent of cases over 14 days, while bismuth-based quadruple therapy succeeded in about 74 percent.18PubMed Central. The Efficacy of Quadruple Therapy Versus Triple Therapy in Helicobacter pylori Eradication Those success rates, frankly, are not great for a bacterial infection in 2025.
The reason treatment success has slipped is antibiotic resistance. Resistance to clarithromycin, metronidazole, and levofloxacin has been climbing steadily, and the rates are now high enough in many regions that experts argue against continuing to prescribe clarithromycin-based therapy without first testing whether the patient’s strain is susceptible.19PubMed Central. Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe After a first treatment failure, the picture gets bleaker. A large population study found that resistance to clarithromycin, levofloxacin, and metronidazole increased over time, and eradication rates with standard triple therapy declined accordingly. Tailoring the antibiotic choice to the individual strain’s susceptibility profile significantly improved outcomes after first-line failure.20PLoS ONE. Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial) The upshot: if your first round of treatment does not work, your doctor ideally should test for resistance before choosing the next regimen.
Effects Beyond the Stomach
H. pylori’s consequences are not limited to the digestive tract. One of the best-documented extra-gastric effects is iron deficiency anemia. The chronic inflammation H. pylori causes in the stomach lining can impair acid production and interfere with the absorption of iron from food, since iron absorption depends on an acidic environment in the upper gut.21Frontiers in Hematology. The nexus between Helicobacter pylori infection and anemia—a systematic review This is particularly relevant in children and adolescents, where persistent H. pylori infection has been linked to recurrent iron deficiency that does not fully respond to iron supplements alone.22PubMed Central. Helicobacter pylori-Associated Iron Deficiency Anemia in Childhood and Adolescence-Pathogenesis and Clinical Management Strategy In cases of unexplained iron deficiency anemia, testing for H. pylori is a reasonable step that some clinicians overlook.
H. Pylori in Children
Most people who carry H. pylori acquired it in childhood, usually before age 10. In developing countries, early childhood infection is the norm. But children’s immune response to the bacterium differs from that of adults. Infected children tend to have milder stomach inflammation and lower rates of ulcers, which researchers attribute to a less aggressive immune cell recruitment in the stomach lining.23PubMed Central. Helicobacter pylori Infections in Children
Treating H. pylori in children is not straightforward. Antibiotic options are more limited in pediatric patients, reinfection rates tend to be higher (especially when other family members remain infected), and a meaningful proportion of childhood infections clear spontaneously without treatment.24PubMed Central. Diagnosis and treatment of Helicobacter pylori infections in children and elderly populations For these reasons, guidelines generally recommend against broad “test and treat” strategies in children and instead advise testing only when there is a clear clinical reason, such as an ulcer or unexplained iron deficiency.
The Paradox of Possible Protective Effects
One of the more counterintuitive findings in H. pylori research is the growing evidence that the bacterium may protect against certain diseases. Multiple studies have found an inverse relationship between H. pylori infection and esophageal adenocarcinoma, the type of esophageal cancer linked to chronic acid reflux. The proposed mechanism involves H. pylori-induced changes in the stomach that reduce acid output over time, thereby lowering the amount of acid that refluxes into the esophagus.25PubMed Central. Is Helicobacter pylori infection protective against esophageal cancer? The majority of observational data support this protective association for both Barrett’s esophagus (a precancerous condition of the esophagus) and esophageal adenocarcinoma.26Journal of Translational Gastroenterology. Impact of Helicobacter pylori Status on GERD, Barrett’s Esophagus and Esophageal Cancer
Similar inverse associations have been reported for allergic asthma. Epidemiological studies suggest that childhood exposure to H. pylori may reduce asthma risk, fitting into a broader “old friends” or hygiene hypothesis about how early microbial exposure shapes the immune system.27International Archives of Allergy and Immunology. The Protective Effects of Helicobacter pylori Infection on Allergic Asthma This creates a genuine clinical dilemma. Eradicating H. pylori eliminates the risk of ulcers and stomach cancer but might remove a brake on reflux disease and possibly allergic conditions. The current medical consensus still favors treatment in symptomatic patients and those at high risk for gastric cancer, but the protective angle is one reason researchers have described eradication as a “double-edged sword.”
What Eradication Does to Your Gut Microbiome
The antibiotic cocktail used to kill H. pylori does not only affect the target bacterium. Research tracking gut bacteria before and after eradication therapy found significant shifts in the microbial community, including a decrease in Bifidobacterium species (which are generally considered beneficial) and changes in the relative abundance of several other bacterial groups. Some of these microbial changes were correlated with alterations in blood sugar regulation after treatment.28PubMed Central. H. pylori eradication with antibiotic treatment causes changes in glucose homeostasis related to modifications in the gut microbiota Whether these microbiome shifts cause lasting metabolic effects or are temporary disruptions that resolve over time is still an open question, but it adds another layer of complexity to the treat-or-don’t-treat calculation for asymptomatic carriers.
Diet, Salt, and Strain Virulence
Not everyone infected with H. pylori faces the same level of risk, and diet appears to be one of the modifiers. In animal studies, a high-salt diet dramatically amplified the cancer-promoting effects of virulent H. pylori strains. Animals infected with a CagA-positive strain and fed a high-salt diet developed gastric cancer at twice the rate of those on a normal diet, with more severe inflammation, higher stomach pH, and greater loss of acid-producing cells.29PubMed Central. High dietary salt intake exacerbates Helicobacter pylori-induced gastric carcinogenesis High salt concentrations actually increased the bacterium’s production of the CagA protein itself, meaning the diet was not just harming the stomach independently but also making the bacterium more virulent. This aligns with long-standing epidemiological observations that populations with high salt intake (through preserved, pickled, or heavily salted foods) have higher rates of stomach cancer, especially when H. pylori prevalence is also high.
Vaccine Prospects
Given how common H. pylori is and how problematic antibiotic resistance has become, a vaccine would be transformative. Proof-of-concept work has shown that vaccination can prevent children from acquiring the infection, and several subunit vaccine candidates have performed well in animal models.30PubMed Central. Status of vaccine research and development for Helicobacter pylori However, progress has been painfully slow. Only one vaccine candidate, based on the UreB protein, has reached Phase III clinical trials.31Journal of Applied Microbiology. Advances and challenges in Helicobacter pylori subunit vaccine development: antigen candidates and immunization strategies No vaccine has been commercialized, and H. pylori vaccine development is not currently a strategic priority for major pharmaceutical companies. The disease burden falls disproportionately on low- and middle-income countries, which limits commercial incentive. Until that changes, antibiotics remain the only option for the billions of people already colonized.
An Ancient Companion
H. pylori has been with us far longer than any antibiotic. Genetic analysis of different H. pylori strains from around the world has revealed that the bacterium’s evolutionary history tracks human migration with striking precision. Because H. pylori is transmitted primarily within families and communities, its genetic lineages diverge and diversify alongside the human populations that carry them. Researchers have used H. pylori genome data to trace Paleolithic migrations across continents, including movements through central Asia and across to the Japanese archipelago tens of thousands of years ago.32iScience. Helicobacter pylori genomes reveal Paleolithic human migration to the east end of Asia The geographic distribution and ethnic associations of different H. pylori populations reflect ancient and historical migrations, making the bacterium a useful genetic marker for piecing together debated chapters of human population history.33PLoS ONE. Evolutionary History of Helicobacter pylori Sequences Reflect Past Human Migrations in Southeast Asia We have been carrying this organism since before we were fully modern in our behavior, and its fate is now entangled with questions about antibiotic stewardship, cancer prevention, and the unintended consequences of eliminating a microbe that, for all its harm, has been part of the human ecosystem for at least a hundred thousand years.